[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Department of Medical Services Ministry of Public Health of Thailand\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100567249","phase-4-outcomes-of-early-and-late-administration-g-csf-for-primary-prophylaxis-in-non-hodgkins-lymphoma-patients-100567249",false,"NCT06665737","Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients","A Comparison Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Who Receive Chemotherapy, Multicenter Study","G-CSF in NHL","Inclusion Criteria:\n\n* Aged 18 years or old\n* Confirmed lymphoma undergoing standard chemotherapy\n* Signed an approval informed consent\n* Has a good understanding of Thai\n* Available for follow-up after chemotherapy\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Serious concomitant diseases and discontinuous treatment such as cardiovascular, liver, or kidney diseases\n* Contraindication to chemotherapy or G-CSF administration\n* Antibiotic use within 1 week prior to enrollment","ALL","18 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to\n\nPrimary Objectives:\n\n1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during standard chemotherapy in a multicenter study\n2. To determine the incidence of leukopenia and neutropenia in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy in a multicenter study\n\nSecondary Objectives:\n\n1. To determine changes in white blood cell, hemoglobin, and platelet levels in patients with non-Hodgkin's lymphoma who received early or late G-CSF during standard chemotherapy.\n2. To determine the quality of life of patients with non-Hodgkin's lymphoma who undergoing standard chemotherapy and with neutropenia Researchers will compare the outcome between patients received either early G-CSF (within 72 hours) or late G-CSF (after 72 hours).\n\nAll patients will be followed up to monitor for febrile neutropenia events, other hematological parameters and quality of life.",[27,28,29,30],"Non-Hodgkin's Lymphoma (NHL)","Granulocyte Colony Stimulating Factor","Febrile Neutropenia (FN)","Myelosuppression Adult",[32,33,28,34],"Non-Hodgkin's lymphoma","Febrile neutropenia","Myelosuppression","NOT_YET_RECRUITING","2025-01-24",{"date":38,"type":39},"2025-01-28","ACTUAL",{"date":41,"type":21},"2025-02-01",{"date":43,"type":21},"2026-12-31",{"name":45,"class":46},"Department of Medical Services Ministry of Public Health of Thailand","OTHER_GOV",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100574768","efficacy-of-surgical-glove-compression-therapy-as-a-prevention-of-paclitaxel-induced-peripheral-neuropathy-100574768","NCT06763575","Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy","Efficacy of Surgical Glove-Compression Therapy As a Prevention of Paclitaxel-Induced Peripheral Neuropathy: Randomized Controlled Trial","Inclusion Criteria:\n\n* Signed Informed Consent Form\n* Age 18 years or older at the time of signing Informed Consent Form\n* Patients with any pathological diagnosis of solid tumor, such as breast cancer or lung cancer\n* Patients scheduled to be receiving intravenous paclitaxel or paclitaxel-based regimen every 3 weeks\n\nExclusion Criteria:\n\n* Patients whose received chemotherapeutic agents that could cause neuropathy, e.g. taxane-based or platinum-based chemotherapy and anti-microtubule\n* History of neuropathy\n* History of carpal tunnel syndrome\n* History of allergic reactions to latex or gloves\n* Patients receiving treatments that may treat neuropathy, e.g. amitriptyline, gabapentin, Acetyl L-Carnitine and Ganglioside-monosialic acid, acupuncture, cryotherapy or exercise therapy\n* History of Raynaud phenomenon\n* History of wounds or large scars on hands\n* Pregnancy or breastfeeding\n* History of poorly controlled diabetes; HbA1c\\>6.5",{"count":55,"type":21},36,[57],"NA","The aim of this randomized controlled trial (RCT) is to compare the incidence of paclitaxel-induced grade 2 or higher sensory peripheral neuropathy, evaluated using the CTCAE version 5.0, between patients receiving surgical glove-compression therapy (SGCT) and those in the control group.\n\nThe main question is whether SGCT is effective in preventing paclitaxel-induced sensory peripheral neuropathy.\n\n* Intervention group: receive SGCT.\n* Control group: receive non-compressive plastic gloves.",[60],"Paclitaxel-induced Peripheral Neuropathy",[62,63,64],"Paclitaxel","Surgical Glove-Compression Therapy","Peripheral Neuropathy","RECRUITING","2025-01-02",{"date":68,"type":39},"2025-01-08",{"date":70,"type":21},"2025-01-01",{"date":72,"type":21},"2026-06-01",{"name":45,"class":46},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":74},"100515339","artificial-intelligence-in-the-detection-of-right-sided-colonic-polyp-in-different-operator-experience-100515339","NCT05990218","Artificial Intelligence in the Detection of Right Sided Colonic Polyp in Different Operator Experience","Efficacy of Artificial Intelligence in the Detection of Right Sided Colonic Polyp in Operators with Different Endoscopic Experience: a Randomized Control Trial","Inclusion Criteria:\n\n* participants age 40-80 years\n\nExclusion Criteria:\n\n* History of colonic surgery (except appendectomy)\n* Lower gastrointestinal bleeding\n* unstable vital sign during endoscopy of pregnancy\n* history of inflammatory bowel disease, polyposis syndrome, colon cancer, colonic stricture, abnormal coaglulation, organ failure",true,"40 Years","80 Years",{"count":86,"type":21},240,[57],"Colonoscopy is the gold standard modality for the detection of colonic polyp. However, miss polyp occurs especially in right sided colon. Artificial intelligence (AI) is one of the modality to improve polyp detection but the benefit of AI in operators with different endoscopic experience is still limited. This study aimed to evaluate the efficacy of AI in the detection of right sided colonic polyp in operators with different endoscopic experience by using double insertion of right side colon, back-to-back basis.",[90],"Colon Polyp",[92,93,94],"colon polyp","artificial intellegence","colonoscopy","2024-12-09",{"date":97,"type":39},"2024-12-13",{"date":99,"type":39},"2023-02-13",{"date":101,"type":21},"2026-02-28",{"name":45,"class":46},""]